More than six decades after thousands of American women were given thalidomide during pregnancy — without the drug ever winning U.S. approval — the children born with severe limb deformities are now adults demanding that the federal government formally acknowledge they exist. Their case challenges the tidy national story in which thalidomide was halted before it could harm anyone on this side of the Atlantic.
The episode began inauspiguously. When the Cincinnati-based pharmaceutical company William S. Merrell applied to the Food and Drug Administration for clearance of a German-made sedative in late 1960, officials expected the review to be quick and the product to be on American store shelves before Christmas. The sedative was thalidomide, and it was not approved that year — or the following one.
The person who stopped it was a persistent medical reviewer, Dr. Frances Oldham Kelsey, a pharmacologist in the agency's Washington offices. Kelsey kept digging into the drug's safety data and refused to let the application pass, and in the process she fundamentally reshaped how the FDA evaluates new medicines — laying groundwork for the testing and approval standards that still govern the agency today. A photograph from Oct. 15, 1962, shows Kelsey holding three packages of Contergan, the German brand name under which thalidomide was sold, a reminder that the product was already circulating abroad while American regulators debated whether it should ever reach patients. President John F. Kennedy publicly credited Kelsey with having spared the United States a human tragedy of the kind that had visited families in Germany.
But that national story, however deserved its reputation, was incomplete. Blocking approval did nothing to stop physicians already prescribing thalidomide to thousands of patients in the United States, including women who were pregnant. Some of the children those women carried were born with severely deformed limbs, a harm that continued after the FDA's gate had closed, because the drug's distribution moved through clinical channels rather than through pharmacy shelves.
Those children are adults now, and among them is Gwen Riechmann, who was born with phocomelia — the shortened, malformed limbs that are the signature birth defect associated with thalidomide exposure in utero. Riechmann's account of the gap between the official record and lived experience is blunt: she says patients today still encounter doctors who insist the thalidomide tragedy was a European phenomenon, something that happened in Germany and Britain but not in the United States. Her response, she said, is simply: oh yeah, it did.
That denial persists partly because the American numbers are small in a way that makes them easy to dismiss. Phocomelia is rare in general, and it is slightly more common outside the United States, particularly in countries such as Britain and Germany, where thalidomide was sold far more widely and the population exposed was correspondingly larger. A low domestic count can be read, mistakenly, as evidence of a low domestic exposure. In Riechmann's own family, the prescribing decision was made in an exam room rather than in a laboratory: when her mother was pregnant with her in the early 1960s, her doctor handed the expectant mother a new sedative, apparently without any sense that the compound was unproven, unapproved or already under scrutiny.
Riechmann is connected to a group of survivors in the Cincinnati area, where Merrell's offices once sat, who have been pressing for recognition and support. Their objective is not to relitigate the drug war of the early 1960s but to correct the historical record: they want the federal government to state plainly that thalidomide was administered to American pregnant patients, that children were harmed, and that those children are alive and living with the consequences today. Official acknowledgment matters to them less as ceremony than as documentation, in a country where their diagnoses have been attributed to chance rather than to a drug.
The survivors' experience also exposes a structural blind spot in the system Kelsey built. The reforms that made the FDA's approval process more rigorous were designed around the danger of dangerous drugs reaching the public through normal channels. They were far less equipped to address a parallel danger: a compound that never cleared those channels but was nevertheless handed to patients by individual physicians, often to women, often during pregnancy, and often without informed consent about what was known and unknown. Kelsey stopped the flood at the regulatory dam; nothing stopped the seepage through the clinic door.
That is why the survivors' request arrives with a time element attached to it. The people who were prescribed thalidomide are elderly, and the children who were born with phocomelia are now middle-aged. The generation that can document the prescribing era from the inside is passing, and with it the firsthand evidence that the drug circulated here. Each year, the story gets harder to prove and easier to deny.
For regulators, the implications reach beyond one drug and one decade. If acknowledgment is granted, it would establish a principle: that being unapproved does not mean being unused, and that national medical history includes the harm of unlicensed prescribing as well as the triumph of licensed review. Kelsey's legacy is secure; what survivors are asking is that the scope of that legacy include the people her actions could not reach.
For now, the federal government has not yet issued the acknowledgment the survivors are seeking. Their request rests on a simple factual claim that the FDA's own historical narrative has not fully absorbed — that the United States did not escape thalidomide, and that the number of Americans living with its effects is larger than official acknowledgments suggest. The argument for recognition, in other words, is not a matter of contested memory but of a registry that has never been made complete.
(0)